off label tirzepatide Mounjaro for Weight Loss: Off-Label Use for Weight Management Our Readers Tried Weight-Loss Drugs

Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication

This makes this medicine more favourable for overweight people with insulin resistance

Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 drugs, are a class of peptide medications ( not dietary supplements ) primarily used to treat type 2 diabetes (T2D) and obesity

The doctors advise on how to deal with nausea caused by semaglutide and tirzepatide use

Do I have to sign a long contract